uniQure(QURE) - 2025 Q1 - Quarterly Results

Exhibit 99.1 uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress ~ AMT-130 granted Breakthrough Therapy designation by FDA~ ~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related serious adverse events ~ ~ Held Type B FDA meetings in the first and second quarters of 2025 to advance BLA preparations for AMT- 130; regulatory update expected in the second quarter of 2025 ~ ~ AMT-26 ...